TCRT
Alaunos Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.63
−1.21%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 3.0K | 5.0K | 10.0K | 5.0K | 2.9M |
| Cost of Revenue | 847.0K | 1.4M | 362.0K | 4.8M | 22.5M |
| Gross Profit | (844.0K) | (1.4M) | (352.0K) | (4.8M) | (19.6M) |
| Operating Expenses | |||||
| R&D Expense | 1.6M | 1.4M | 362.0K | 16.3M | 25.0M |
| SG&A Expense | 2.4M | 2.9M | 4.5M | 12.2M | 13.1M |
| General & Admin Expense | 2.4M | 2.9M | 4.5M | 12.2M | 13.1M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (838.0K) | (1.4M) | (362.0K) | 971.0K | (22.7M) |
| Total Operating Expenses | 3.2M | 2.9M | 4.5M | 29.5M | 15.5M |
| Cost and Expenses | 4.1M | 4.2M | 4.8M | 34.3M | 38.0M |
| Operating Income (EBIT) | (4.1M) | (4.2M) | (4.8M) | (34.3M) | (35.1M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | 1.9M | 3.2M |
| Net Interest Income | — | — | — | (1.9M) | (3.2M) |
| Other Non-Op Income/Expense | 48.0K | 49.0K | 133.0K | (873.0K) | (2.6M) |
| Non-Operating Income (excl Interest) | (48.0K) | (49.0K) | (133.0K) | (1.0M) | (529.0K) |
| EBT (Pre-Tax Income) | (4.0M) | (4.2M) | (4.7M) | (35.1M) | (37.7M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (4.0M) | (4.2M) | (4.7M) | (35.1M) | (37.7M) |
| Earnings from Cont. Ops | (4.0M) | (4.2M) | (4.7M) | (35.1M) | (37.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (4.1M) | (4.2M) | (4.7M) | (35.1M) | (37.7M) |
| Per Share | |||||
| Basic EPS | ($1.95) | ($2.20) | ($2.92) | ($21.97) | ($25.97) |
| Diluted EPS | ($1.95) | ($2.20) | ($2.92) | ($21.97) | ($25.97) |
| Revenue Per Share | $0.00 | $0.00 | $0.01 | $0.00 | $2.02 |
| Shares | |||||
| Basic Shares Outstanding | 2.4M | 1.9M | 1.6M | 1.6M | 1.4M |
| Diluted Shares Outstanding | 2.4M | 1.9M | 1.6M | 1.6M | 1.4M |
| Profitability Metrics | |||||
| EBITDA | (4.0M) | (4.2M) | (4.7M) | (30.9M) | (31.8M) |
| D&A | 24.0K | 7.0K | 2.0K | 2.3M | 2.8M |
| EBIT | (4.0M) | (4.2M) | (4.7M) | (33.2M) | (34.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026